<DOC>
	<DOC>NCT01847092</DOC>
	<brief_summary>The purpose of this study is to determine if the study drug is safe, tolerable and active in reducing albuminuria in patients with Chronic Kidney Disease with Type 2 Diabetes.</brief_summary>
	<brief_title>A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Albuminuria</mesh_term>
	<criteria>Males or females aged 18 to 80 years, inclusive. Body mass index between 18 and 45 kg/m2, inclusive. Type 2 diabetes mellitus and receiving ≥1 glucose lowering medication for at least 3 months prior to randomization Stage 3 CKD MSSBP ≥130 mmHg Urinary albumin: mean UACR ≥ 200 mg/g Urinary albumin: UACR &gt; 3500 mg/g History of a renal transplant MSSBP &gt;180 mmHg or a MSDBP of &gt;120 mmHg on two occasions during screening or runin periods History of inflammatory bowel disease or diarrhea predominant irritable bowel syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>albuminuria</keyword>
</DOC>